BlackRock Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

BlackRock Advisors’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$607K	Buy	16,027 +2,987	+23%	+$113K	﹤0.01%	2098
2016 Q3	$492K	Buy	13,040 +730	+6%	+$16.1K	﹤0.01%	2185
2016 Q2	$217K	Buy	12,310 +1,608	+15%	+$26K	﹤0.01%	2557
2016 Q1	$130K	Buy	10,702 +649	+6%	+$10.3K	﹤0.01%	2786
2015 Q4	$245K	Sell	10,053 -4,185	-29%	-$97.7K	﹤0.01%	2466
2015 Q3	$253K	Buy	14,238 +1,487	+12%	+$26.9K	﹤0.01%	2592
2015 Q2	$225K	Buy	12,751 +5,775	+83%	+$106K	﹤0.01%	2732
2015 Q1	$219K	Buy	6,976 +892	+15%	+$25.9K	﹤0.01%	2622
2014 Q4	$178K	Sell	6,084 -190	-3%	-$4.82K	﹤0.01%	2703
2014 Q3	$130K	Sell	6,274 -20,361	-76%	-$401K	﹤0.01%	2860
2014 Q2	$660K	Sell	26,635 -6,101	-19%	-$106K	﹤0.01%	1807
2014 Q1	$694K	Buy	32,736 +16,210	+98%	+$328K	﹤0.01%	1811
2013 Q4	$297K	Buy	+16,526	New	+$215K	﹤0.01%	2407

Other funds holding AERI

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Advisors's AERI Position: Q4 2016 in Review

BlackRock Advisors increased its Aerie Pharmaceuticals (AERI) stake by 23% in Q4 2016, buying an estimated $113K and bringing the position to 16,027 shares worth $607K. The position accounts for ﹤0.01% of the portfolio, ranked #2098.

BlackRock Advisors first reported a position in AERI in Q4 2013 and has held it in 13 quarters since. The position peaked at $694K in Q1 2014. 151 funds tracked by Wall St. Rank hold AERI as of Q4 2016.

BlackRock Advisors held 16,027 shares of Aerie Pharmaceuticals worth $607K as of Q4 2016.
BlackRock Advisors bought 2,987 Aerie Pharmaceuticals shares in Q4 2016, an estimated $113K.
Aerie Pharmaceuticals made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2098 holding.
BlackRock Advisors first reported a position in Aerie Pharmaceuticals in Q4 2013 and has held it in 13 quarters since.
BlackRock Advisors's Aerie Pharmaceuticals position peaked at $694K in Q1 2014.
151 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.